Cibus, Inc.
NASDAQ:CBUSBiotechnology
+$0.04 today
- Market cap
- $104.71M
- Beta
- 1.65
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.16
Volume 0.25M
Average 0.51M
CBUS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cibus, Inc.NASDAQ: CBUS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $8.72M fell 26.1% year over year, behind the -18.1% change in trailing-twelve-month research & development. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at +56.4% a year.
Context
- Research & development amounted to 1214.6% of revenue in FY2025, up 31.3 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -26.1% toward the trailing-twelve-month pace of -18.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 44.2M USD
- Year-over-year change
- -12.4%
- 4-year CAGR
- +40.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.2M | -12.4% |
| FY2024 | 2024-12-31 | 50.43M | +19.0% |
| FY2023 | 2023-12-31 | 42.37M | +266.7% |
| FY2022 | 2022-12-31 | 11.55M | +1.9% |
| FY2021 | 2021-12-31 | 11.34M | — |
Research & Development vs competitors
How CBUS compares with its peers on the latest reported figures
- CBUS's LTM Mar 2026 research & development of $41.12M is the 7th highest of the 10 companies compared; the peer median is $59.66M.
- Its year-over-year change of -18.1% is the 7th highest of 10, against a peer median of -3.9%.
- Research & development amounts to 959.3% of revenue for CBUS, versus a peer median of 958.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.27B | +18127.2% | -7.8% | 212494.0% | |
| LTM Mar 2026 | $200.25M | +133.0% | +35.5% | 78.3% | |
| LTM Mar 2026 | $86.08M | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $67.7M | +8.5% | +10.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59.66M | -11.8% | +35.8% | — |
| LTM Mar 2026 | $48.2M | -55.0% | -0.4% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $41.12M | -18.1% | +56.4% | 959.3% |
| LTM Mar 2026 | $37.7M | -3.9% | — | 958.2% | |
| LTM Mar 2026 | $23.02M | -48.6% | -81.3% | — | |
| LTM Mar 2026 | $8.57M | -44.2% | -9.8% | — | |
| Peer median (excluding CBUS) | $59.66M | -3.9% | +2.2% | 958.2% | |
Competitors are the stored peer set for CBUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 25.99M | 157K | 1.82M | 4.26M | 3.64M |
| Cost of Revenue | 28.56M | 1.53M | 395K | 0 | 5.92M |
| Gross Profit | (2.57M) | (1.38M) | 1.42M | 4.26M | (2.28M) |
| Gross Margin | -9.9% | -877.1% | 78.3% | 100.0% | -62.8% |
| Research & Development | 11.34M | 11.55M | 42.37M | 50.43M | 44.2M |
| Selling, General & Admin | 15.38M | 9.44M | 28.91M | 30.8M | 26.91M |
| Operating Expenses | 26.76M | 20.99M | 320.31M | 262.66M | 65.18M |
| Depreciation & Amortization | 2.34M | 1.53M | 4.69M | 6.86M | 5.92M |
| EBITDA | (25.43M) | (15.21M) | (314.59M) | (241.64M) | (90.77M) |
| EBITDA Margin | -97.9% | -9687.9% | -17313.4% | -5669.5% | -2494.3% |
| Operating Income | (29.33M) | (22.37M) | (318.88M) | (258.4M) | (67.46M) |
| Operating Margin | -112.9% | -14248.4% | -17550.0% | -6062.8% | -1853.9% |
| Interest Income | 17K | 60K | 527K | 631K | 438K |
| Interest Expense | 1.43M | 87K | 18.89M | 34.19M | 35.48M |
| Other Income / Expenses | 133K | 5.48M | (18.76M) | (24.29M) | (64.71M) |
| Income Before Tax | (29.2M) | (16.89M) | (337.64M) | (282.68M) | (132.17M) |
| Pre-Tax Margin | -112.4% | -10758.6% | -18582.4% | -6632.7% | -3632.1% |
| Income Tax Expense | 0 | 0 | (4K) | 29K | 29K |
| Net Income | (29.2M) | (16.89M) | (267.63M) | (251.39M) | (127.09M) |
| Net Margin | -112.4% | -10758.6% | -14729.1% | -5898.4% | -3492.3% |
| EPS (Basic) | (0.05) | (0.03) | (25.95) | (10.83) | (2.78) |
| EPS (Diluted) | (0.05) | (0.03) | (25.95) | (10.83) | (2.78) |
| Weighted Avg Shares | 578.47M | 578.47M | 10.31M | 23.22M | 457.57M |
| Weighted Avg Shares (Diluted) | 578.47M | 578.47M | 10.31M | 23.22M | 457.57M |
Cibus, Inc.
NASDAQ:CBUS
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.